Chronic Kidney Disease

AstraZeneca unveils Phase III kidney treatment results

15-Sep-2020 By Jenni Spinner

In a Phase III trial, Farxiga reportedly showed reduction in the risk of kidney failure, and cardiovascular (CV) or renal death, in CKD patients.

Frenova launches startup acceleration program

20-Jun-2016 By Melissa Fassbender

Frenova Renal Research has launched its inaugural group of site businesses which comprise F1RST Up – a program designed to accelerate study startup by eliminating common administrative and contracting issues.

Pfizer calls on Evotec for tissue fibrosis drug discovery

10-Sep-2015 By Gareth Macdonald

Evotec has added Pfizer to its roster of Big Pharma partners through a drug discovery agreement focused on tissue fibrosis.

CROs DaVita Clinical Research, HealthCare Partners Clinical Research to merge

17-Dec-2014 By Zachary Brennan

CROs are consolidating further, this time with DaVita HealthCare Partners’ business units DaVita Clinical Research (DCR) and HealthCare Partners Clinical Research merging to further expand their services, specifically for patients with chronic kidney...

Covance, Frenova team to share and analyze data on CKD, renal disease

23-Sep-2014 By Zachary Brennan

CRO Covance and Fresenius subsidiary Frenova Renal Research are collaborating to find more effective treatments for patients living with chronic kidney disease (CKD) and end stage renal disease (ESRD).

NextPharma Picked for Packaging Mitsubishi's BindRen

10-Jun-2013 By Dan Stanton

NextPharma has won a contract to provide packaging solutions for Mitsubishi Pharma's chronic kidney disease drug in Europe.

Amgen and Ortho Biotech breathe collective sigh of relief after FDA panel vote

13-Sep-2007 By Emilie Reymond

Amgen and Ortho Biotech are breathing a sigh of relief after a
regulatory committee recommended not to change the label on their
blockbuster anaemia drugs when used in the kidney failure setting.

Amgen bolsters portfolio in kidney disease via $420m buy

05-Jun-2007 By Cristina Jimenez-Andres

Amgen will strengthen its drug portfolio aimed at fighting renal
disease after agreeing to acquire Ilypsa, a private biotechnology
company which is developing a novel drug for the treatment of
elevated blood phosphate (hyperphosphataemia)...

Genzyme given green light to make kidney drug at Irish plant

14-Aug-2006 By Kirsty Barnes

US biotech firm Genzyme has been given a green light by the US Food
and Drug Administration (FDA) to begin manufacturing its kidney
drug at its Waterford facility in Ireland.

Ilypsa completes trial into next-gen nonabsorbed polymeric drug

02-May-2006 By Wai Lang Chu

Ilypsa has completed the first stage of its novel phosphate-binding
agent designed to treat hyperphosphatemia, as the company plough
forward with its pioneering research into next-generation
nonabsorbed polymeric drugs for renal and...

Gambro's renal monitors banned from US

16-Jan-2006 By Kirsty Barnes

Global medical technology company Gambro has had imports of its
kidney dialysis monitors into the US blocked by the US Food and
Drug Administration (FDA) after a failed plant inspection in
September.

Genzyme unveils $540m expansion plan for manufacturing, R&D

27-Sep-2005

US biotechnology major Genzyme officially opened four European
facilities last week as part of a investment package eventually
expected to cost $540 million (€449m).

Side effect concerns recede for Eprex

07-Apr-2003

The latest data on cases of antibody-mediated pure red cell aplasia
associated with Johnson & Johnson subsidiary Janssen-Cilag's
erythropoietin product Eprex/Erypo (epoetin alfa) have suggested
that measures put in place...